General Nieuws Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN januari 20, 2021
General Nieuws Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN november 9, 2020
General Nieuws Regulated Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer EN oktober 13, 2020
General Nieuws Regulated Oxurion NV – Expert Presentation of Positive Topline Data from a Phase 1 Study evaluating THR-687 for the treatment of DME, at Angiogenesis, Exudation, and Degeneration 2020 Conference EN februari 9, 2020
General Nieuws Regulated Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference EN februari 5, 2020
General Nieuws Regulated Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME EN januari 7, 2020
General Nieuws Regulated Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME EN december 19, 2019
General Nieuws Regulated Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME EN september 9, 2019
General Nieuws Regulated Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME EN augustus 20, 2019
Nieuws Regulated Transparency/Denominator Regulated information – Transparency Statement OXUR shares EN NL mei 10, 2019
Nieuws Regulated Transparency/Denominator Regulated information – Transparency Statement Clay EN NL mei 10, 2019
